[GAMUDA] YoY Annualized Quarter Result on 31-Oct-2018 [#1]

Stock
[GAMUDA] GAMUDA BHD
Announcement Date
14-Dec-2018
Admission Sponsor
-
Sponsor
-
Financial Year
31-Jul-2019
Quarter
31-Oct-2018 [#1]
Profit Trend
QoQ- 33.91%
YoY- -15.26%
Quarter Report
Latest QR
Upcoming QR
GAMUDA's Result
GAMUDA's Financial Summary
View:
Show?
Annualized Quarter Result
31/10/21 31/10/20 31/10/19 31/10/18 31/10/17 31/10/16 31/10/15 CAGR
Revenue 2,988,456 3,055,816 4,383,316 3,615,528 3,087,292 2,019,524 2,051,180 6.46%
PBT 766,052 563,260 871,860 904,644 1,037,304 822,588 770,200 -0.08%
Tax -109,104 -80,888 -129,496 -158,856 -166,204 -122,460 -78,748 5.57%
NP 656,948 482,372 742,364 745,788 871,100 700,128 691,452 -0.84%
-
NP to SH 609,476 437,132 694,460 688,152 812,068 648,592 644,932 -0.93%
-
Tax Rate 14.24% 14.36% 14.85% 17.56% 16.02% 14.89% 10.22% -
Total Cost 2,331,508 2,573,444 3,640,952 2,869,740 2,216,192 1,319,396 1,359,728 9.39%
-
Net Worth 9,274,920 8,571,129 8,284,814 7,799,714 7,656,779 7,139,352 6,641,837 5.71%
Dividend
31/10/21 31/10/20 31/10/19 31/10/18 31/10/17 31/10/16 31/10/15 CAGR
Div 603,246 - 593,538 592,383 588,983 580,828 577,551 0.72%
Div Payout % 98.98% - 85.47% 86.08% 72.53% 89.55% 89.55% -
Equity
31/10/21 31/10/20 31/10/19 31/10/18 31/10/17 31/10/16 31/10/15 CAGR
Net Worth 9,274,920 8,571,129 8,284,814 7,799,714 7,656,779 7,139,352 6,641,837 5.71%
NOSH 2,513,528 2,513,527 2,473,407 2,468,264 2,455,000 2,420,119 2,406,462 0.72%
Ratio Analysis
31/10/21 31/10/20 31/10/19 31/10/18 31/10/17 31/10/16 31/10/15 CAGR
NP Margin 21.98% 15.79% 16.94% 20.63% 28.22% 34.67% 33.71% -
ROE 6.57% 5.10% 8.38% 8.82% 10.61% 9.08% 9.71% -
Per Share
31/10/21 31/10/20 31/10/19 31/10/18 31/10/17 31/10/16 31/10/15 CAGR
RPS 118.89 121.57 177.24 146.48 125.80 83.45 85.24 5.69%
EPS 24.24 17.40 28.08 27.88 33.08 26.80 26.80 -1.65%
DPS 24.00 0.00 24.00 24.00 24.00 24.00 24.00 0.00%
NAPS 3.69 3.41 3.35 3.16 3.12 2.95 2.76 4.95%
Adjusted Per Share Value based on latest NOSH - 2,468,264
31/10/21 31/10/20 31/10/19 31/10/18 31/10/17 31/10/16 31/10/15 CAGR
RPS 105.08 107.45 154.13 127.13 108.56 71.01 72.13 6.46%
EPS 21.43 15.37 24.42 24.20 28.55 22.81 22.68 -0.93%
DPS 21.21 0.00 20.87 20.83 20.71 20.42 20.31 0.72%
NAPS 3.2613 3.0139 2.9132 2.7426 2.6924 2.5104 2.3355 5.71%
Price Multiplier on Financial Quarter End Date
31/10/21 31/10/20 31/10/19 31/10/18 31/10/17 31/10/16 31/10/15 CAGR
Date 29/10/21 30/10/20 31/10/19 31/10/18 31/10/17 31/10/16 30/10/15 -
Price 3.24 3.33 3.74 2.39 5.25 4.91 4.50 -
P/RPS 2.73 2.74 2.11 1.63 4.17 5.88 5.28 -10.40%
P/EPS 13.36 19.15 13.32 8.57 15.87 18.32 16.79 -3.73%
EY 7.48 5.22 7.51 11.67 6.30 5.46 5.96 3.85%
DY 7.41 0.00 6.42 10.04 4.57 4.89 5.33 5.63%
P/NAPS 0.88 0.98 1.12 0.76 1.68 1.66 1.63 -9.75%
Price Multiplier on Announcement Date
31/10/21 31/10/20 31/10/19 31/10/18 31/10/17 31/10/16 31/10/15 CAGR
Date 21/12/21 21/12/20 13/12/19 14/12/18 15/12/17 16/12/16 16/12/15 -
Price 2.92 3.86 3.78 2.28 4.75 4.81 4.40 -
P/RPS 2.46 3.18 2.13 1.56 3.78 5.76 5.16 -11.60%
P/EPS 12.04 22.20 13.46 8.18 14.35 17.95 16.42 -5.03%
EY 8.30 4.51 7.43 12.23 6.97 5.57 6.09 5.29%
DY 8.22 0.00 6.35 10.53 5.05 4.99 5.45 7.08%
P/NAPS 0.79 1.13 1.13 0.72 1.52 1.63 1.59 -10.99%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment